期刊文献+

IMP3在子宫内膜癌中的表达及意义 被引量:2

Expression and significance of IMP3 in endometrial carcinoma
下载PDF
导出
摘要 目的探讨胰岛素样生长因子ⅡmRNA结合蛋白3(insulin-like growth factorⅡmRNA binding protein3,IMP3)在子宫内膜癌中的表达及意义。方法选取子宫内膜癌70例,包括子宫内膜样癌52例及子宫浆液性腺癌18例,采用免疫组化Envision法检测IMP3的表达,同时对不同组织学类型及分级的肿瘤中IMP3的表达进行比较。结果 IMP3的++以上表达率在子宫内膜样癌与浆液性腺癌中分别为17.3%与88.9%,差异有统计学意义(P<0.01);在高、中、低分化子宫内膜癌中的表达率分别为16.1%、31.8%及70.5%,高中分化组与低分化组相比差异有统计学意义(P<0.05)。结论 IMP3在子宫内膜癌中的过度表达主要出现在浆液性腺癌中,并与肿瘤的恶性生物学行为相关。IMP3检测有助于子宫内膜癌的鉴别诊断及预后评估。 Objective The expression of insulin-like growth factor Ⅱ mRNA binding protein3(IMP3) in endometrial carcinomas was detected to explore it’s significance in development of tumor, differential diagnosis and prognosis. Methods 70 endometrial carcinomas including 52 endometrioid carcinomas and 18 serous carcinomas were selected and expression of IMP3 was detected by using immunohistochemistry Envision method. The positive rates were compared respectively in different histological type and grade. Results IMP3 located mainly in the cytoplasm of tumor cells and the positive rate above 50%was set as the dividing value. Statistics showed that the positive expression rate of IMP3 in endometrioid carcinomas and serous carcinomas was 17.3%and 88.9%respectively, there was a significant difference between two groups(P〈0.01).IMP3 expressed 16.1%,31.8%,70.5%positively in well, moderate, and poor-differentiated EC respectively, it showed significant difference between moderate group and poor group(P〈0.05). Conclusion IMP3 plays an important role in the development of EC and expresses excessively in serous carcinoma specifically. Its expression rate shows closely correlation with the malignant biological characteristics thus to be a valuable indicator for differential diagnosis and prognosis evaluation of EC.
出处 《中国实用医药》 2014年第3期9-10,共2页 China Practical Medicine
关键词 子宫内膜癌 IMP3 免疫组织化学 Endometrial carcinoma IMP3 Immunohistochemistry
  • 相关文献

参考文献2

二级参考文献33

  • 1McCluggage WG. biomarkers of value in female genital tract and functional lesions [ J ]. Int J Gynecol Pathol, 2006, 25(2) :101 -120.
  • 2Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological 18(6) :415 -437 features [J]. Adv Anat Pathol, 2011.
  • 3Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometfial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes [ J ]. Int J Gynecol Pathol, 2010, 29(4) :343 -350.
  • 4Alkushi A, Lim P, Coldman A, et al. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level [ J ]. Int J Gynecol Pathol, 2004, 23(2) :129 - 137.
  • 5Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes [J]. Mod Pathol, 2010, 23( 1 ) : 80 - 92.
  • 6Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3 : a novel biomarker for endometrial serous carcinoma [ J ]. Am J Surg Pathol, 2008, 32(2) :304 -315.
  • 7Zhang X, Liang SX, Jia L, et al. Molecular identification of "latent preeancers" for endometrial serous carcinoma in benign- appearing endometrium [J]. Am J Pathol, 2009, 174(6) :2000 - 2006.
  • 8Vang R, Bamer R, Wheeler DT, et al staining for Ki-67 and p53 helps distinguish endometrial Arias- Stella reaction from high-grade carcinoma, including clear cell carcinoma [J]. Int J Gyneeol Pathol, 2004, 23(2):223 -233.
  • 9Nieolae A, Preda O, Nogales FF. Endometrial metaplasias and reactive changes : a spectrum of altered differentiation [ J ]. J Clin Pathol, 2011, 64(2) :97 - 106.
  • 10O'Neill CJ, McCluggage WG. p16 expression in the female genital tract and its value in diagnosis [ J ]. Adv Anat Pathol, 2006, 13(1) :8 -15.

共引文献31

同被引文献14

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部